Successful treatment of refractory enteropathy-associated T-cell lymphoma using high-dose chemotherapy and autologous stem cell transplantation

Intern Med. 2010;49(19):2157-61. doi: 10.2169/internalmedicine.49.3409. Epub 2010 Oct 1.

Abstract

A 65-year-old woman presented with a 6-month history of abdominal pain and watery diarrhea. Type II enteropathy-associated T-cell lymphoma (EATL) was diagnosed based on the clinical presentation and pathological examination of the tumor. The patient received combination chemotherapy but did not achieve remission. Subsequently, high-dose therapy (HDT) and autologous stem cell transplantation (ASCT) were performed. After these therapies, she achieved complete remission, which has been sustained for 18 months. Although the role of HDT-ASCT for EATL is still controversial, the clinical course of this patient suggests that ASCT can improve the prognosis in some patients with EATL.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Combined Modality Therapy
  • Cyclophosphamide / administration & dosage
  • Doxorubicin / administration & dosage
  • Doxorubicin / analogs & derivatives
  • Enteropathy-Associated T-Cell Lymphoma / drug therapy*
  • Enteropathy-Associated T-Cell Lymphoma / therapy*
  • Female
  • Humans
  • Jejunal Neoplasms / drug therapy*
  • Jejunal Neoplasms / therapy*
  • Peripheral Blood Stem Cell Transplantation*
  • Prednisolone / administration & dosage
  • Remission Induction
  • Transplantation, Autologous
  • Vincristine / administration & dosage

Substances

  • Vincristine
  • Doxorubicin
  • Cyclophosphamide
  • Prednisolone

Supplementary concepts

  • VEP-THP protocol